HOLOGIC, INC. MARLBOROUGH, Mass., April 27, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal second quarter ended March 26, 2016. GAAP diluted earnings per share (EPS) of $0.24 increased 41.2%, and non-GAAP diluted EPS of $0.47 increased 14.6%. Revenue of $693.3 million increased 5.8% on a reported basis, and 6.3% on a constant currency basis.
"We posted another good quarter, highlighted by 14.6% growth in non-GAAP EPS," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer. "The strength of our business model was evident at multiple levels in the quarter. Our U.S. businesses grew revenue at a double-digit rate, we improved both gross and operating margins while making significant investments in our future, and we aggressively redeployed capital, leading to EPS growth more than double the rate of sales."
Key financial results for the fiscal second quarter are shown below. Throughout this press release, all dollar figures are in millions, except EPS. Unless otherwise noted, all results are on a reported basis, and are compared to the prior year period.
GAAP Non-GAAP
---- --------
Q2'16 Q2'15 Change Q2'16 Q2'15 Change
----- ----- ------ ----- ----- ------
Revenues $693.3 $655.5 5.8% $693.3 $655.5 5.8%
-------- ------ ------ --- ------ ------ ---
Gross Margin 55.5% 51.3% 420 bps 65.8% 63.4% 240 bps
------------ ---- ---- ------- ---- ---- -------
Operating
Expenses $248.9 $226.2 10.1% $221.2 $195.9 12.9%
--------- ------ ------ ---- ------ ------ ----
Operating
Margin 19.6% 16.8% 280 bps 33.9% 33.5% 40 bps
--------- ---- ---- ------- ---- ---- ------
Net Income $68.9 $47.8 44.1% $135.7 $118.9 14.1%
---------- ----- ----- ---- ------ ------ ----
Diluted EPS $0.24 $0.17 41.2% $0.47 $0.41 14.6%
----------- ----- ----- ---- ----- ----- ----
Revenue Detail
Revenues grew in three of four business segments globally, with the highest growth rate in the GYN Surgical division:
$s in millions Q2'16 Q2'15 Change Change
(Reported) (Constant Currency)
--- --------- ------------------
Cytology & Perinatal $116.1 $113.3 2.5% 3.5%
Molecular
Diagnostics 126.1 119.7 5.4% 5.8%
Blood Screening 62.2 63.7 (2.4%) (2.4%)
--------------- ---- ---- ----- -----
Total Diagnostics $304.4 $296.7 2.6% 3.2%
----------------- ------ ------ --- ---
Breast Imaging 232.3 211.0 10.1% 10.5%
Interventional
Breast Solutions 41.5 42.7 (2.7%) (2.4%)
Other 2.0 1.8 9.3% 13.4%
----- --- --- --- ----
Total Breast Health $275.8 $255.5 8.0% 8.4%
------------------- ------ ------ --- ---
GYN Surgical $90.9 $79.1 14.9% 15.9%
------------ ----- ----- ---- ----
Skeletal Health $22.2 $24.2 (8.5%) (8.2%)
--------------- ----- ----- ----- -----
Total $693.3 $655.5 5.8% 6.3%
----- ------ ------ --- ---
Other revenue highlights:
-- U.S. sales of $547.9 million increased 10.6%, continuing strong recent
trends.
-- International sales of $145.4 million decreased (9.3%) on a reported
basis, or (7.0%) in constant currency, driven by inventory fluctuations
in blood screening and discontinued products in Breast Health.
Excluding these two factors, international sales increased slightly in
the quarter on a constant currency basis.
-- Breast Health revenue totaled $275.8 million, an increase of 8.0% on a
reported basis, or 8.4% in constant currency. In the United States,
revenue increased 11.2%, as adoption of Hologic's Genius(TM) 3D
Mammography(TM) systems continued to grow. Internationally, revenue
declined (5.5%) on a reported basis, or (3.3%) in constant currency.
However, excluding sales of discontinued products from the prior year
period, international revenues increased at a low-single-digit rate.
-- In Diagnostics:
-- Molecular diagnostics sales of $126.1 million increased 5.4% on a
reported basis, or 5.8% in constant currency. Growth was primarily
driven by continued strength across Aptima® women's health products
on the fully automated Panther® and Tigris® platforms,
particularly in the United States.
-- Cytology and perinatal sales of $116.1 million increased 2.5% on a
reported basis, or 3.5% in constant currency. Of note, U.S. sales
increased at a mid-single-digit rate.
-- Blood screening revenue totaled $62.2 million, a decrease of (2.4%)
on both a reported and constant currency basis that was driven
primarily by ordering patterns by Hologic's partner Grifols.
-- In GYN Surgical, MyoSure® sales of $35.4 million increased 29.2% on a
reported basis, or 29.8% in constant currency. NovaSure® sales of
$55.2 million increased 8.1% on a reported basis, or 9.3% in constant
currency.
-- In Skeletal Health, revenue of $22.2 million declined (8.5%) on a
reported basis, or (8.2%) in constant currency, due primarily to
distributor ordering patterns internationally.
Segment revenue highlights by geography are shown below:
U.S. Change International Change International Change
(Reported) (Constant Currency)
--------- ------------------
Diagnostics 9.4% (13.2%) (11.2%)
----------- --- ------ ------
Breast
Health 11.2% (5.5%) (3.3%)
------- ---- ----- -----
GYN
Surgical 14.3% 18.5% 25.4%
--------- ---- ---- ----
Skeletal
Health 3.3% (25.1%) (24.3%)
-------- --- ------ ------
Total
Revenues 10.6% (9.3%) (7.0%)
--------- ---- ----- -----
Expense Detail
Gross margin was 55.5% on a GAAP basis, and 65.8% on a non-GAAP basis. Compared to the prior year period, non-GAAP gross margin improved 240 basis points, mainly due to strong domestic sales growth, favorable product mix, and operational improvements.
Operating expenses were $248.9 million on a GAAP basis, and $221.2 million on a non-GAAP basis. Operating expenses increased mainly due to planned investments in Breast Health and Diagnostics marketing, and research and development.
Other Key Financial Results
Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) were $253.8 million in the fiscal second quarter, an increase of 6.4% compared to the prior year period.
Total debt outstanding at the end of the quarter was $3.4 billion, a decrease of ($0.5) billion compared to the prior year period.
The combination of lower debt and EBITDA growth has helped improve Hologic's leverage ratio (net debt over EBITDA) to 3.1 times.
Strong profit growth and lower debt have improved Hologic's return on invested capital (ROIC), which was 11.7% on a trailing 12 months basis, a 170 basis point increase compared to the prior year period.
Hologic redeployed cash aggressively in the quarter to continue improving its capital structure and enhance future earnings power. The Company repurchased $90 million of its 2010 Convertible Notes for $140.1 million, and $136.6 million of its 2012 Convertible Notes for $171.3 million. In addition, the Company repurchased 4.3 million shares of its common stock for $148.8 million.
Financial Guidance for Fiscal 2016
The guidance below is based on recent foreign exchange rates, a full-year tax rate of approximately 33%, and diluted shares outstanding of approximately 292 million for the full year.
Current Guidance Previous Guidance Current Guidance vs. Prior
Year Current Guidance vs.
Prior Year
(As Reported)
(Constant Currency)
------------------
Revenues $2,810 to $2,830 million $2,800 to $2,830 million 3.9% to 4.6% 4.6% to 5.4%
-------- ------------------------ ------------------------ ----------- -----------
Non-GAAP EPS $1.89 to $1.91 $1.86 to $1.90 13.2% to 14.4% 14.6% to 15.8%
------------ -------------- -------------- ------------- -------------
For the third quarter of fiscal 2016, Hologic expects:
Current Guidance Current Guidance vs. Prior Year Current Guidance vs.
Period (As Reported) Prior Year Period
(Constant Currency)
------------------
Revenues $695 to $705 million 0.2% to 1.6% 0.6% to 2.0%
-------- -------------------- ----------- -----------
Non-GAAP EPS $0.47 to $0.48 9.3% to 11.6% 10.1% to 12.4%
------------ -------------- ------------ -------------
Use of Non-GAAP Financial Measures
The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP net income; non-GAAP EPS; adjusted EBITDA; and return on invested capital (ROIC). The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill and intangible assets; (ii) additional depreciation expense from acquired fixed assets and accelerated depreciation related to consolidation and closure of facilities; (iii) non-cash interest expense related to amortization of the debt discount from the equity conversion option of the convertible notes; (iv) restructuring and divestiture charges and facility and consolidation charges; (v) debt extinguishment losses and related transaction costs; (vi) unrealized gains/losses attributable to recording forward foreign currency contracts to fair value for which the company has not elected hedge accounting; (vii) litigation settlement charges (benefits); (viii) other-than-temporary impairment losses on investments and realized gains resulting from the sale of investments; (ix) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (x) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines ROIC as its net operating profit after tax on a trailing twelve month basis divided by average net debt plus average stockholders' equity.
These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The company's definition of these non-GAAP measures may differ from similarly titled measures used by others.
The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic's business.
Because non-GAAP financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
Future Non-GAAP Adjustments
Future GAAP EPS may be affected by changes in ongoing assumptions and judgments, and may also be affected by non-recurring, unusual or unanticipated charges, expenses or gains, which are excluded in the calculation of the Company's non-GAAP EPS guidance as described in this press release. It is therefore not practicable to reconcile non-GAAP EPS guidance to the most comparable GAAP measure.
Conference Call and Webcast
Hologic's management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the second quarter of fiscal 2016. Approximately 10 minutes before the call, dial 888-455-2271 (U.S. and Canada) or 719-325-2444 (international) and enter access code 2794619. A replay will be available starting two hours after the call ends through May 27, 2016 at 888-203-1112 (U.S. and Canada) or 719-457-0820 (international), access code 2794619. The Company will also provide a live webcast of the call at http://investors.hologic.com.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, Genius 3D Mammography, Aptima, ThinPrep, MyoSure, NovaSure, Panther, Tigris, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herein based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect the Company's business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees; U.S., European and general worldwide economic conditions and related uncertainties; the Company's reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; uncertainties regarding healthcare reform legislation, including associated tax provisions, or budget reduction or other cost containment efforts; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company's products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company's ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company's international activities and businesses; manufacturing risks, including the Company's reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the Company's leverage risks, including the Company's obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.
The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Contact
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
HOLOGIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and per share data)
Three Months Ended Six Months Ended
March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015
-------------- -------------- -------------- --------------
Revenues:
Product $583.0 $546.4 $1,170.2 $1,093.0
Service and other 110.3 109.1 218.2 215.3
----- ----- ----- -----
Total revenues 693.3 655.5 1,388.4 1,308.3
----- ----- ------- -------
Cost of revenues:
Product 182.0 186.7 370.1 373.4
Amortization of intangible assets 70.8 78.6 144.3 152.5
Service and other 55.5 54.2 109.9 107.8
---- ---- ----- -----
Gross profit 385.0 336.0 764.1 674.6
----- ----- ----- -----
Operating expenses:
Research and development 59.1 53.3 110.8 105.2
Selling and marketing 100.8 83.0 200.3 169.0
General and administrative 62.4 60.3 139.5 121.7
Amortization of intangible assets 22.8 27.6 45.4 55.4
Restructuring and divestiture charges 3.8 2.0 6.0 10.0
Total operating expenses 248.9 226.2 502.0 461.3
----- ----- ----- -----
Income from operations 136.1 109.8 262.1 213.3
Interest income 0.2 0.3 0.4 0.7
Interest expense (39.1) (49.4) (78.3) (101.9)
Debt extinguishment loss (4.5) - (4.5) (6.7)
Other income (expense), net (0.8) 0.1 26.9 (0.5)
---- --- ---- ----
Income before income taxes 91.9 60.8 206.6 104.9
Provision for income taxes 23.0 13.0 52.8 27.9
---- ---- ---- ----
Net income $68.9 $47.8 $153.8 $77.0
===== ===== ====== =====
Net income per common share:
Basic $0.24 $0.17 $0.54 $0.28
===== ===== ===== =====
Diluted $0.24 $0.17 $0.53 $0.27
===== ===== ===== =====
Weighted average number of shares outstanding:
Basic 282,474 280,338 282,725 279,505
======= ======= ======= =======
Diluted 287,857 287,580 289,914 285,378
======= ======= ======= =======
HOLOGIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions)
March 26, 2016 September 26,
2015
-------------- --------------
ASSETS
Current assets:
Cash and
cash
equivalents $316.3 $492.7
Accounts
receivable,
net 422.6 416.1
Inventories 285.1 283.1
Deferred
income
taxes - 19.0
Other
current
assets 68.6 55.5
Total
current
assets 1,092.6 1,266.4
------- -------
Property,
plant and
equipment,
net 454.1 457.1
Goodwill
and
intangible
assets 5,643.9 5,831.4
Other
assets 95.7 115.2
Total
assets $7,286.3 $7,670.1
======== ========
LIABILITIES AND
STOCKHOLDERS' EQUITY
Current liabilities:
Current
portion
of long-
term debt $307.7 $391.8
Accounts
payable
and
accrued
liabilities 382.4 389.1
Deferred
revenue 150.9 163.1
----- -----
Total
current
liabilities 841.0 944.0
----- -----
Long-term
debt, net
of
current
portion 3,098.0 3,248.0
Deferred
income
taxes 1,071.0 1,178.4
Other
long-
term
liabilities 231.9 220.5
----- -----
Total
liabilities 5,241.9 5,590.9
Total
stockholders'
equity 2,044.4 2,079.2
Total
liabilities
and
stockholders'
equity $7,286.3 $7,670.1
======== ========
HOLOGIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in millions)
Six Months Ended
March 26, 2016 March 28, 2015
-------------- --------------
OPERATING ACTIVITIES
Net income $153.8 $77.0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation 40.2 40.7
Amortization 189.7 207.9
Non-cash interest expense 26.1 33.2
Stock-based compensation expense 30.6 25.8
Excess tax benefit related to equity awards (7.9) (6.0)
Deferred income taxes (64.7) (79.1)
Gain on sale of available-for-sale marketable security (25.1) -
Debt extinguishment loss 4.5 6.7
Other 1.0 3.9
Changes in operating assets and liabilities:
Accounts receivable (7.0) 3.3
Inventories (2.3) 29.0
Prepaid income taxes 3.4 1.3
Prepaid expenses and other assets (15.0) (2.6)
Accounts payable 1.6 (17.8)
Accrued expenses and other liabilities (2.1) (19.3)
Deferred revenue (12.4) 7.3
Net cash provided by operating activities 314.4 311.3
----- -----
INVESTING ACTIVITIES
Purchase of property and equipment (19.4) (20.0)
Increase in equipment under customer usage agreements (22.3) (19.7)
Proceeds from sale of available-for-sale marketable security 31.1 -
Purchases of insurance contracts (5.2) (6.4)
Sales of mutual funds 5.2 7.7
Purchase of intellectual property (4.0) -
Increase in other assets 0.1 (0.6)
Net cash used in investing activities (14.5) (39.0)
----- -----
FINANCING ACTIVITIES
Repayment of long-term debt (37.5) (357.5)
Repurchase of common stock (135.9) -
Payments to extinguish convertible notes (311.5) -
Proceeds from amounts borrowed under revolving credit line 50.0 -
Repayment of amounts borrowed under revolving credit line (50.0) -
Purchase of interest rate caps - (6.1)
Net proceeds from issuance of common stock pursuant to employee stock plans 19.0 37.4
Excess tax benefit related to equity awards 7.9 6.0
Payment of minimum tax withholdings on net share settlements of equity awards (15.6) (12.1)
Net cash used in financing activities (473.6) (332.3)
Effect of exchange rate changes on cash and cash equivalents (1.3) (5.6)
Net decrease in cash and cash equivalents (175.0) (65.6)
Cash and cash equivalents, beginning of period 491.3 736.1
Cash and cash equivalents, end of period $316.3 $670.5
====== ======
HOLOGIC, INC.
RECONCILIATION OF GAAP TO NON-GAAP RESULTS
(Unaudited)
(In millions, except earnings per share and margin percentages)
Three Months Ended Six Months Ended
------------------ ----------------
March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015
-------------- -------------- -------------- --------------
Gross Profit:
GAAP gross profit $385.0 $336.0 $764.1 $674.6
Adjustments:
Amortization of intangible assets (1) 70.8 78.6 144.3 152.5
Incremental depreciation expense (2) 0.5 0.8 1.0 1.6
Integration/consolidation costs (3) - 0.1 - 0.3
Non-GAAP gross profit $456.3 $415.5 $909.4 $829.0
====== ====== ====== ======
Gross Margin Percentage:
GAAP gross margin percentage 55.5% 51.3% 55.0% 51.6%
Impact of adjustments above 10.3% 12.1% 10.5% 11.8%
Non-GAAP gross margin percentage 65.8% 63.4% 65.5% 63.4%
==== ==== ==== ====
Operating Expenses:
GAAP operating expenses $248.9 $226.2 $502.0 $461.3
Adjustments:
Amortization of intangible assets (1) (22.8) (27.6) (45.4) (55.4)
Incremental depreciation expense (2) (0.9) (0.7) (1.8) (1.3)
Integration/consolidation costs (3) (0.2) - (0.4) -
Restructuring and divestiture charges (3) (3.8) (2.0) (6.0) (10.0)
Other (4) - - (6.0) (0.1)
Non-GAAP operating expenses $221.2 $195.9 $442.4 $394.5
====== ====== ====== ======
Operating Margin:
GAAP income from operations 136.1 109.8 262.1 213.3
Adjustments to gross profit as detailed above 71.3 79.5 145.3 154.4
Adjustments to operating expenses as detailed above 27.7 30.3 59.6 66.8
Non-GAAP income from operations $235.1 $219.6 $467.0 $434.5
====== ====== ====== ======
Operating Margin Percentage:
GAAP income from operations margin percentage 19.6% 16.8% 18.9% 16.3%
Impact of adjustments above 14.3% 16.7% 14.7% 16.9%
Non-GAAP operating margin percentage 33.9% 33.5% 33.6% 33.2%
==== ==== ==== ====
Interest Expense:
GAAP interest expense $39.1 $49.4 78.3 101.9
Adjustments:
Non-cash interest expense relating to convertible notes (5) (5.8) (9.0) (12.2) (17.8)
Non-GAAP interest expense $33.3 $40.4 $66.1 $84.1
===== ===== ===== =====
Pre-Tax Income:
GAAP pre-tax earnings $91.9 $60.8 206.6 104.9
Adjustments to pre-tax earnings as detailed above 104.8 118.7 217.1 239.1
Debt extinguishment loss (6) 4.5 - 4.5 6.7
Gain on sale of available-for-sale marketable security (7) - - (25.1) -
Unrealized (gains) losses on forward foreign currency contracts (8) 0.7 - (0.3) -
Non-GAAP pre-tax Income $201.9 $179.5 402.8 350.7
====== ====== ===== =====
Net income:
GAAP net income $68.9 $47.8 $153.8 $77.0
Adjustments:
Amortization of intangible assets (1) 93.6 106.2 189.7 207.9
Non-cash interest expense relating to convertible notes (5) 5.8 9.0 12.2 17.8
Restructuring, divestiture and integration/consolidation costs (3) 4.0 2.1 6.4 10.4
Incremental depreciation expenses (2) 1.4 1.4 2.8 2.9
Debt extinguishment loss (6) 4.5 - 4.5 6.7
Gain on sale of available-for-sale marketable security (7) - - (25.1) -
Unrealized (gains) losses on forward foreign currency contracts (8) 0.7 - (0.3) -
Other charges (4) - - 6.0 0.1
Income tax effect of reconciling items (9) (43.2) (47.6) (79.2) (92.2)
----- ----- ----- -----
Non-GAAP net income $135.7 $118.9 $270.8 $230.6
====== ====== ====== ======
Earnings per share:
GAAP earnings per share - Diluted $0.24 $0.17 $0.53 $0.27
Adjustment to net earnings (as detailed above) 0.23 0.24 0.40 0.54
---- ---- ---- ----
Non-GAAP earnings per share - diluted (10) $0.47 $0.41 $0.93 $0.81
===== ===== ===== =====
Adjusted EBITDA:
Non-GAAP net income $135.7 $118.9 $270.8 $230.6
Interest expense, net, not adjusted above 33.1 40.2 65.7 83.4
Provision for income taxes 66.1 60.6 131.9 120.1
Depreciation expense, not adjusted above 18.9 18.9 37.4 37.6
---- ---- ---- ----
Adjusted EBITDA $253.8 $238.6 $505.8 $471.7
====== ====== ====== ======
Explanatory Notes to Reconciliations:
(1) To reflect non-cash expenses attributable to the amortization of intangible assets.
(2) To reflect non-cash fair value adjustments for additional depreciation expense related to the fair value write-up of fixed assets acquired in the Gen-Probe acquisition and accelerated depreciation expense related to facility closure and consolidation.
(3) To reflect restructuring and divestiture charges and certain costs associated with the Company's integration and facility consolidation plans, which primarily includes retention and transfer costs.
(4) To reflect the net impact from miscellaneous transactions during the relevant period, including legal settlements.
(5) To reflect certain non-cash interest expense related to the amortization of the debt discount from the equity conversion option of the Company's convertible notes.
(6) To reflect losses for partial extinguishment related to voluntary prepayments under the Prior Credit Agreement for the six months ended March 28, 2015 and repurchases of $90.0 million of the 2010 Convertible Notes and $136.6 million of the 2012 Convertible Notes, and related cash transaction costs for the three and six months
ended March 26, 2016.
(7) To reflect realized gain on sale of available-for-sale marketable security.
(8) To reflect non-cash unrealized (gains) and losses on the market-to market on outstanding forward foreign currency contracts for which the Company has not elected hedge accounting.
(9) To reflect an estimated annual effective tax rate of 32.75% and 34.25% for fiscal 2016 and 2015.
(10) Non-GAAP earnings per share was calculated based on 287,857 and 287,580 weighted average diluted shares outstanding for the three months ended March 26, 2016 and March 28, 2015, respectively, and 289,914 and 285,378 weighted average diluted shares outstanding for the six months ended March 26, 2016 and March 28, 2015,
respectively.
Trailing Twelve Months
ended
March 26, 2016
--------------
Return on Invested Capital:
Adjusted Net Operating Profit
After Tax
Net income 524.9
Provision for income taxes 264.2
Interest expense 143.5
Other expense 0.3
Adjusted net operating profit
before tax 932.9
Non-GAAP average effective tax
rate (1) 33.50 %
Adjusted net operating profit
after tax 620.4
=====
Average Net Debt plus Average
Stockholders' Equity (2)
Average total debt 3,672.7
Less: Average cash, cash
equivalents and restricted cash (495.7)
Average net debt 3,177.0
Average stockholders' equity (3) 2,138.7
Average net debt plus average
stockholders' equity 5,315.7
=======
Adjusted ROIC
Adjusted ROIC (adjusted net
operating profit after tax 11.67 %
above divided by average net debt
plus stockholders' equity above)
(1) ROIC is presented on a TTM
basis; non-GAAP effective
tax rate for the three months
ended June 27, 2015 and
September 26, 2015 was 34.25%
and the three months ended
December 26, 2015 and March
26, 2016 was 32.75%.
(2) Calculated using the average
of the balances as of March
26, 2016 and March 28, 2015.
Adjusted (increased) to
eliminate the effect of the
impairment of intangible
assets of $32.2 million in
(3) fiscal 2014.
Three Months
Ended
March 26,
2016
----------
Leverage Ratio:
Total principal debt 3,460.7
Total cash (316.3)
Net principal debt, as
adjusted 3,144.4
EBITDA for the last four
quarters 1,006.5
Leverage Ratio 3.12
====
Other Supplemental Information:
Three Months Ended Six Months Ended
March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015
-------------- -------------- -------------- --------------
Geographic Revenues
U.S. 79.0% 75.5% 78.7% 74.8%
Europe 10.4% 11.8% 10.2% 12.7%
Asia-Pacific 7.4% 8.9% 7.6% 8.8%
All Others 3.2% 3.8% 3.5% 3.7%
Total Revenues 100.0% 100.0% 100.0% 100.0%
===== ===== ===== =====
Revenue Composition
Q2'16
-----
Disposables 60.9%
Capital Equipment 23.2%
Service & Other 15.9%
----
Total Revenues 100.0%
=====
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hologic-announces-financial-results-for-second-quarter-of-fiscal-2016-300258430.html
SOURCE Hologic, Inc.
